Alcon Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Alcon is de winst gegroeid met een gemiddeld jaarlijks percentage van 66.4%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 12.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 7% per jaar. Het rendement op eigen vermogen van Alcon is 5.3%, en het heeft een nettomarge van 11.4%.

Belangrijke informatie

66.4%

Groei van de winst

66.4%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	7.0%
Rendement op eigen vermogen	5.3%
Nettomarge	11.4%
Volgende winstupdate	13 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis

Apr 28

Alcon: Global Leader In An Attractive End-Market

Dec 16

Alcon Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Alcon Q3 2020 Earnings Preview

Nov 09

Opbrengsten en kosten

Hoe Alcon geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSE:ALC Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	9,636	1,102	3,231	836
31 Mar 24	9,562	1,048	3,226	842
31 Dec 23	9,455	974	3,209	845
30 Sep 23	9,274	450	3,177	837
30 Jun 23	9,085	362	3,141	795
31 Mar 23	8,880	341	3,112	759
31 Dec 22	8,717	335	3,068	723
30 Sep 22	8,695	571	3,131	684
30 Jun 22	8,657	457	3,145	706
31 Mar 22	8,550	460	3,125	703
31 Dec 21	8,291	376	3,076	703
30 Sep 21	8,082	332	2,980	706
30 Jun 21	7,818	183	2,884	680
31 Mar 21	6,922	-390	2,690	665
31 Dec 20	6,833	-531	2,694	675
30 Sep 20	6,806	-717	2,647	678
30 Jun 20	6,836	-636	2,662	702
31 Mar 20	7,525	-604	2,827	707
31 Dec 19	7,508	-656	2,802	690
30 Sep 19	7,386	-638	2,830	735
30 Jun 19	7,280	-779	2,827	688
31 Mar 19	7,177	-362	2,761	665
31 Dec 18	7,153	-227	2,799	653
30 Sep 18	7,123	175	2,725	527
31 Dec 17	6,792	256	2,596	545
31 Dec 16	6,596	-170	2,526	481
31 Dec 15	6,776	308	2,337	457

Kwaliteitswinsten: ALC heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (11.4%) ALC } zijn hoger dan vorig jaar (4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ALC is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 66.4% per jaar laten groeien.

Versnelling van de groei: De winstgroei van ALC over het afgelopen jaar ( 204.4% ) overtreft het 5-jarig gemiddelde ( 66.4% per jaar).

Winst versus industrie: De winstgroei ALC over het afgelopen jaar ( 204.4% ) overtrof de Medical Equipment -sector 11.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 5.3% ) van ALC wordt als laag beschouwd.

Alcon Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 21% undervalued

Alcon: Trading At An Undeserved Premium Valuation

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings: EPS exceeds analyst expectations

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Upcoming dividend of CHF0.16 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Dividend of CHF0.16 announced

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

Alcon: Lackluster Growth Given Its Valuation

Alcon: The Steady Force Of 'Boring'

Price target increased by 8.4% to US$85.32

Price target increased by 7.9% to US$84.07

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.14 per share at 0.3% yield

Full year 2022 earnings: EPS misses analyst expectations

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon reached $199M settlement with J&J Surgical Vision

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon a buy at Mizuho on 'eyecare dominance'

Alcon Inc. Updates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Q3 2022 Earnings Preview

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon: Looking To Break Downtrend Before Entry

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Alcon downgraded to hold at Societe Generale on macro headwinds

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

Alcon: Revisiting The Investment Thesis

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Upcoming dividend of CHF0.13 per share

The Recent Pullback Makes Alcon More Attractive

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon: Good Quarterly Results, But It Is Still Expensive

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)